Allarity Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. November 12, 2024 Deadline to file Lead Plaintiff Motion.

Core Viewpoint - Allarity Therapeutics, Inc. is facing a class action lawsuit due to allegations of issuing materially false and misleading statements regarding its business practices and regulatory compliance during the specified class period from May 17, 2022, to July 19, 2024 [1][2]. Group 1: Legal Proceedings - Investors have until November 12, 2024, to file a lead plaintiff motion in the class action lawsuit [1]. - The lawsuit claims that Allarity and its former officers engaged in improper conduct related to the Dovitinib NDA, which has led to increased regulatory scrutiny and potential legal repercussions [2]. Group 2: Company Misconduct - The complaint asserts that the defendants inflated the regulatory prospects of the Dovitinib NDA and downplayed the likelihood of enforcement actions following the investigation into the company's practices [2]. - This misconduct has exposed Allarity to significant legal, financial, and reputational damages [2].